Arbutus Biopharma (ABUS) announced that it has reacquired China rights to its lead compound, imdusiran, from Qilu Pharmaceutical. The parties have mutually agreed to conclude the strategic partnership entered into in 2021 for development, manufacturing and commercialization of imdusiran in mainland China, Hong Kong, Macau and Taiwan markets. Arbutus has also launched a new Scientific Advisory Board, SAB, which will include: Jordan Feld, Edward Gane, Anna Suk-Fong Lok, Mark Sulkowski, and Man-Fung Yuen.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABUS:
- Arbutus Biopharma Holds Annual Shareholder Meeting
- Mount Logan Capital Reports Q1 2025 Financial Results
- Arbutus Biopharma Achieves Milestones in Hepatitis B Treatment and Expands Leadership
- Arbutus Biopharma reports Q1 EPS (13c), consensus (15c)
- Arbutus Biopharma Unveils Promising HBV Treatment Data